The 2023 ASCO Annual Meeting opened grandly on June 2 in Chicago. As one of the most influential international academic conferences in the field of oncology, this session attracted many global oncology pharmaceutical companies, enterprises in the area of oncology, as well as researchers to participate in and share cutting-edge research results.

Building the Bridge of International Exchange and Cooperation

After three years, we once again witness the dense academic atmosphere of ASCO. OrigiMed's featured booth (booth number: 23113) shows innovative technologies and academic strength of Chinese enterprises to the world, becoming a bridge for communication between domestic and international clinical experts and pharmaceutical partners.

The Latest Research on MRD in Sarcoma—Selected for Oral Abstract Session

At the 2023 ASCO Annual Meeting, the latest research "The Clinical Value of Tumor-informed Minimal Residual Disease Detection in Sarcoma", which is completed by Professor Junqiang Yin from the department of musculoskeletal oncology of the First Affiliated Hospital of Sun Yat-sen University and OrigiMed, was selected for Oral Abstract Session. This is the only Chinese study selected for the Clinical Science Symposium and fills the gap of international research about MRD in sarcoma. On the afternoon of June 2nd, Professor Junqiang Yin was invited to give an oral presentation on this research at the ASCO Annual Meeting. The lively discussion on site indicates the high level of clinical attention it has received.

The study achieved significant progress in the dynamic monitoring and efficacy prediction of MRD in sarcoma by conducting tumor-informed MRD detection for 84 sarcoma patients. The overall success rate of personalized MRD customization was 78.6%. The results showed that more than half of these sarcoma patients had unique tumor mutation genes, making them more suitable for tumor-informed MRD detection. At baseline detection, ctDNA could be detected completely, and postoperative MRD results could indicate the recurrence and metastasis of sarcoma earlier than imaging.

Achievements Displayed on the Poster Attract Much Attention

In the Poster Discussion Session, a study on novel LTK fusions based on NGS sequencing data in Chinese solid tumor patients, brought by OrigiMed, has been attracting a great deal of attention from clinical physicians. This study retrospectively analyzed 11 Chinese solid tumor patients using OrigiMed's Yuan Su S (NGS DNA+RNA), revealing distributions of novel LTK fusions among Chinese solid tumor patients. At the DNA level, 6 patients were found to have LTK fusions, including lung adenocarcinoma, colon cancer, gastric cancer, small intestine spindle cell sarcoma, pancreatic cancer, and cancer of unknown primary origin. At the RNA level, 5 patients with soft tissue sarcoma had the RPAP1 E25-LTK E2 fusion. To date, there have been few reports of LTK fusions, and detailed analysis of these fusions has enriched our understanding and attention to their potential value in clinical treatment.